EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. TAP
3. DELL
4. ROIV
5. ANET
6. NKE
7. BE
8. PANW
9. CL
10. SNDK

Go back to EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
(NASDAQ: EYPT) Delayed: 4.58 --0 (-0%)
Previous Close $4.58    52 Week High $ 
Open $4.58    52 Week Low $ 
Day High $4.58    P/E N/A 
Day Low $4.58    EPS $ 
Volume 74,120